Shouyao Holdings(SH:688197) Xin Lang Zheng Quan·2025-10-31 16:45Core Viewpoint - Shouyao Holdings, established in April 2016 and listed on the Shanghai Stock Exchange in March 2022, focuses on the research and development of small molecule anti-tumor drugs, showcasing significant R&D capabilities and high investment value [1] Business Performance - For Q3 2025, Shouyao Holdings reported revenue of 2 million yuan, ranking 109 out of 110 companies in the industry. The top company, Huadong Medicine, achieved revenue of 32.664 billion yuan, while the industry average was 2.8 billion yuan [2] - The net profit for the same period was -155 million yuan, placing the company at 100 out of 110 in the industry. The leading company, Hengrui Medicine, reported a net profit of 5.76 billion yuan, with the industry average at 299 million yuan [2] Financial Ratios - As of Q3 2025, Shouyao Holdings had a debt-to-asset ratio of 14.11%, up from 12.57% year-on-year, which is below the industry average of 35.26% [3] - The gross profit margin stood at 100%, unchanged from the previous year and higher than the industry average of 57.17% [3] Executive Compensation - Chairman Li Wenjun's salary decreased from 672,700 yuan in 2023 to 580,600 yuan in 2024, a reduction of 92,100 yuan [4] Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 13.70% to 5,146, while the average number of circulating A-shares held per household decreased by 12.05% to 12,400 [5] - The largest circulating shareholder is Penghua Medical Technology Stock A, holding 5.4079 million shares, unchanged from the previous period [5] Future Prospects - Shouyao Holdings is expected to achieve significant milestones in commercialization and R&D, with the second-generation ALK inhibitor SY-707 anticipated to be approved in 2026, and the third-generation ALK inhibitor SY-3505 showing promising clinical value [5] - Revenue projections for 2025 to 2027 are 15 million yuan, 96 million yuan, and 285 million yuan, with year-on-year growth rates of 280.5%, 537.7%, and 197.8% respectively [5] - Net profits for the same period are projected to be -183 million yuan, -208 million yuan, and -112 million yuan [5]